Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 13;8(6):494-499.
doi: 10.1089/trgh.2021.0205. eCollection 2023 Dec.

Testosterone Pellet Use in Transgender Men

Kwan Cheng  1 , Aren Skolnick  1
Affiliations

Testosterone Pellet Use in Transgender Men

Kwan Cheng et al. Transgend Health. .

Abstract

Purpose: We assessed the efficacy and short-term adverse effects of testosterone pellet use in transgender men to broaden therapeutic options.

Methods: We conducted a retrospective study of 30 transgender men who started testosterone pellets between 2018 and 2020.

Results: Testosterone pellets were started at dosages 675-825 mg per cycle and dose was adjusted according to testosterone levels obtained 1 to 6 months post-testosterone pellet insertion. Pharmacokinetics of testosterone pellet in transgender men was similar to those in cisgender men. Total testosterone levels reached a peak in 1 month and remained in the therapeutic range for ∼4 months in the range of 300-800 ng/dL. After switching over to testosterone pellets, 100% of patients continued to achieve amenorrhea and deepening of their voice. Most of the patients noticed increased hair growth in androgen-dependent regions (96.3%) and improved libido (70%). Adverse events were notable for a rate of polycythemia that was unexpectedly high at 46.67%. Pellet extrusion was found in 13.33% of patients. There was a low rate of pellet site hematoma (6.67%) and cellulitis (3.33%). No thromboembolic or cardiovascular events occurred in any of the patients.

Conclusion: This study reveals that testosterone pellets are a reasonable alternative to other testosterone modalities in transgender men but would use caution in patients with a history of polycythemia or higher risk for thromboembolic events.

Keywords: erythrocytosis; testosterone pellet; transgender; transgender man.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any financial disclosures to make.

Figures

FIG. 1.
FIG. 1.
Total testosterone levels (blue line) by months after testosterone pellet insertion.
See this image and copyright information in PMC

References

    1. Conron KJ, Scott G, Stowell GS, et al. . Transgender health in Massachusetts: Results from a household probability sample of adults. Am J Public Health 2012;102(1):118–122; doi: 10.2105/AJPH.2011.300315. - DOI - PMC - PubMed
    1. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. . Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102(11):3869–3903; doi: 10.1210/jc.2017-01658. - DOI - PubMed
    1. Handelsman DJ, Conway AJ, Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 1990;71(1):216–222; doi: 10.1210/jcem-71-1-216. - DOI - PubMed
    1. Deutsch MB. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. UCSF Gender Affirming Health Program, Department of Family and Community Medicine, University of California San Francisco; 2016. Available from: https://transcare.ucsf.edu/guidelines [Last accessed: January 25, 2021].
    1. Kaminetsky JC, Moclair B, Hemani M, et al. . A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. J Sex Med 2011;8(4):1186–1196; doi: 10.1111/j.1743-6109.2010.02196.x. - DOI - PubMed

LinkOut - more resources